Topic: acute lymphoblastic leukemia

England's cost-effectiveness watchdogs gave Novartis the go-ahead for its CAR-T drug, Kymriah, to treat leukemia.

If the competition between Novartis and Gilead in relapsed large B-cell lymphoma comes down to price, it will be a close race.

Kite's new CAR-T approval vaults it and new parent Gilead into a market first launched by Novartis—and into the debate over high drug prices.

Steve Miller, CMO of Express Scripts, is not mincing words in his assessment of Kymriah, Novartis' $475,000 CAR-T treatment for leukemia.

Cancer patient and advocate David Mitchell visited Novartis to discuss what a fair price might be for its CAR-T treatment, but he left disappointed.

Pfizer has rebuked U.K. drug cost watchdog NICE for its refusal to recommend approval of the drugmaker's new targeted leukemia treatment.

One cancer patient is urging Novartis to weigh taxpayer investment in early-stage CAR-T science in setting a price on its new med tisagenlecleucel.

Pfizer today won FDA approval for a new targeted drug for the treatment of relapsed or refractory acute lymphoblastic leukemia.

Novartis won crucial backing for its potentially groundbreaking CAR-T drug at an FDA expert panel on Wednesday.

Manufacturing costs are a significant factor in pricing CAR-T cancer meds because of the intensive process required for the personalized treatments.